Human rhinoviruses (HRVs) are members of the family Picornaviridae and comprise over 100 serotypes. They are major causative agents of the common cold and, although generally causing only mild symptoms, they account for approximately 50 % of all respiratory tract infections (Sperber & Hayden, 1988) . They are therefore a major cause of lost man-hours at work in Western countries and are thus of considerable economic importance. No commercial vaccine to prevent infection has been developed, due mainly to the antigenic diversity of the virus, but it may be possible to create appropriate peptide immunogens which overcome the limitations of serotype-specific responses (Parry et al., 1989) . We previously reported that a peptide corresponding to residues 156-170 of VP2 of HRV2 can elicit antibodies that neutralize virus infectivity, either when coupled to keyhole limpet haemocyanin (KLH) or when synthesized coUinearly with specific T cell epitopes (Francis et al., 1987 (Francis et al., , 1989 . In common with antisera against peptides derived from other picornaviruses however, neutralization titres correlated poorly with assays of either antivirus or anti-peptide activity and we speculated that this * Author for correspondence. Present address: BBSRC Institute for Animal Health, Ash Road, Pirbright, Woking, Surrey GU24 0NF, UK. Fax +44 483 232448. may be due to the induction of a spectrum of antibodies with different specificities. To analyse the anti-peptide response further we produced a panel of monoclonal antibodies (MAbs) to HRV2 VP2 156-170 peptides and characterized their reactions with a range of antigens (Barnett et al., 1993) . They could be classified into four main reaction groups: Group 1 MAbs, which recognized and neutralized native virus; group 2 MAbs, which bound to intact virus particles, but failed to neutralize infectivity; group 3 MAbs, which recognized virus only after capsid distortions and group 4 MAbs, which were peptide-specific. All of the MAbs isolated recognized the homologous peptide. We have now determined the minimum sequence required to bind each MAb, to ascertain whether there is a correlation between biological activity, as delineated by reaction group, and epitope specificity, in an attempt to define factors which could lead to an improvement in the proportion of the biologically relevant response to peptide immunogens.
A set of overlapping peptides was synthesized, using conventional tert-butyloxycarbonyl (t-Boc) chemistry (Merrifield, 1963) and the 'tea-bag' method of Houghten (1985) , as a series of 15 amino acid blocks frame-shifted by two residues at a time to span, in total, the 141-184 region of HRV2 VP2. Each peptide also had an 'unnatural' cysteine at its C terminus. The minimum binding footprint for each MAb was determined from 0001-2952 © 1995 SGM The resolution of the mapping assay was limited slightly because the 15 amino acid blocks used were frame-shifted by two amino acids, rather than one, at a time. However, the results show that representative MAbs from reaction groups 1-3 can share the same minimum binding sequence. Furthermore, the amino acid 156-170 sequence contained at least two overlapping neutralization epitopes, comprising residues 156-163 and 160-165, respectively. With three of the group 4 MAbs (P008, P007 and P011) the entire 15 residue peptide used as the immunogen was required for antibody recognition, possibly indicating conformational constraints. In contrast, the smallest and most common epitope size determined with the HRV2 anti-peptide MAbs was six residues in length.
It is interesting to note that MAbs which recognized a minimum binding sequence that incorporated residues to the C-terminal side of the aspartic acid at position D165 did not, in general, react with intact virus. This suggests that the C-terminal end of the sequence, when constrained in the quaternary structure of the virus particle, may be either inaccessible to antibodies or in a conformation which is not mimicked by free peptide. Although the three-dimensional structure of HRV2 has yet to be determined, structural co-ordinates are avail- Short communication able for the closely related HRV1A (Kim et al., 1989) . By analogy with HRV1A, the 156-170 sequence of HRV2 VP2 should form a prominent loop at the surface of the virus (Fig. 1) which lies on the southern rim of the 'canyon', the proposed site of cell attachment (Rossmann et al., 1985; Colonno et al., 1988) . For HRV1A, residues on the C-terminal side of amino acid R165 contribute increasingly to the base of this loop, with a concomitant decreasing accessibility to antibodies, although amino acid insertions and deletions complicate exact sequence alignments between HRV1A and HRV2 in this region of VP2. Recently, however, Tormo et al. (1994) have elucidated the crystal structure of the 156-170 peptide complexed with the neutralizing anti-HRV2 MAb 8F5 (Skern et al., 1987) and shown that both main chain atoms and side chain orientations of residues 157-164 of the bound peptide can be closely superimposed on residues 159-166 of HRV1A. After these points the structures become progressively divergent to such an extent that it is unlikely that the structure of the peptide is approximating that of the parent virus.
The abilities of group 1 anti-peptide MAbs, polyclonal anti-virus and anti-peptide sera, and three anti-virus MAbs (801, 822 and 829; Appleyard et al., 1990) to neutralize variants of HRV2 were compared using a chequerboard dose-response test similar to that described by Booth et al. (1978) . In this, doubling dilutions of antibody were reacted with half log10 dilutions of virus for 2 h before adding HeLa cells as indicators of residual infectivity. Following incubation at 34 °C for 5 days, fixing and staining, antibody titres were calculated as the reciprocal antibody dilution required for 50 % neutralization of 100 TCIDs0 from regression analysis. Two natural isolates of HRV2 were included in these studies: HRV2 Vienna, described by Skern et al. (1985) , from which the synthetic peptide sequence was derived, and HRV2 Wellcome, which was used to raise the anti-viral MAbs. The latter differs from the Vienna strain only by an A158T change in VP2 (Appleyard et al., 1990) . The six other strains were antibody-selected mutants. PEP1, with a P164H substitution in VP2, was obtained from HRV2 Vienna under selective pressure from rabbit polyclonal antiserum to KLH-coupled VP2 peptide 156-170C. The remaining five strains were variants of the Wellcome virus which had been selected with MAbs recognizing site B of HRV2 (Appleyard et al., 1990) , which is partly analogous to the NIM II site of HRV14 (Sherry et al., 1986) . Thus, in addition to the A158T change, four of these viruses had substitutions in VP2 at amino acid 163 or 164 and one had a substitution at amino acid 264 of VP1 (Fig. 2) .
The mutants could not be differentiated either from each other or from the two natural isolates using polyclonal guinea-pig serum against either HRV2 Wellcome or HRV2 Vienna (Fig. 2) . In contrast, mutants with amino acid substitutions within the 156-170 region of VP2 showed varying degrees of resistance to rabbit anti-HRV2 Vienna peptide 156-170C-KLH polyclonal serum. Neutralization titres were reduced to less than 4% by substitutions at positions N163 or P164 and to approximately 50 % by the substitution A158T in HRV2 Wellcome. The change at residue 158 could also be distinguished by two similar anti-HRV2 Wellcome MAbs, 801 and 829, which had neutralization titres against HRV2 Vienna of 46% and 67% less, respectively, than against the homologous Wellcome strain. These MAbs were unable to neutralize mutants with substitutions at position P164, but neutralized N163 mutants to a similar or greater degree as HRV2 Wellcome, depending on the nature of the substitution. Enhanced neutralization was conferred by the replacement of asparagine with tyrosine, whereas replacement with serine had no effect. In contrast, anti-viral MAb 822 neutralized HRV2 Wellcome and HRV2 Vienna equally, but was incapable of neutralizing the mutants with sequence changes at position N163. Its ability to neutralize mutants with substitutions at residue P164 was dependent on the replacement amino acid, ranging from leucine, which conferred little resistance, to histidine which conferred substantial resistance.
The ability of anti-peptide polyclonal serum and two of the anti-virus MAbs (801 and 829) to distinguish between Vienna and Wellcome strains with a sequence difference at position 158 of VP2 was not shared by the three group 1 anti-peptide MAbs. This suggests that the neutralizing polyclonal antibody repertoire elicited by peptide 156-170 was not fully represented by the MAbs isolated, although it should be noted that the polyclonal serum was raised to KLH-coupled peptide whereas the MAbs were induced by an uncoupled collinear peptide. It is, however, consistent with the mapping data, as is the finding that all tested substitutions at both positions N163 and P164 conferred resistance to anti-peptide MAbs P024 and P027, apparently by preventing antibody binding (Table 2 ). Substitutions at these positions also greatly reduced the ability of non-neutralizing group 2 MAbs to bind virus ( Table 2 ), indicating that group 1 and group 2 MAbs can share the same critical residues as well as a minimum binding sequence.
Anti-peptide MAb P033 had a different reactivity pattern to those of anti-peptide MAbs P024 and P027. As with anti-viral MAbs (Appleyard et al., 1990 ) the neutralizing activity of MAb P033 was partially abrogated by a substitution in VP1 at position 264. Since P033 was raised against VP2 156-170, the substitution at VP1 264 must sterically affect the epitope recognized by the antibody, as has been seen in other systems (Ibrahimi (Skern et al., 1985) . Virus mutant PEP1 (Vienna) was selected with to polyclonal rabbit antiserum raised to KLH-coupled peptide 156-170. Virus mutant 806R 1 (Wellcome) was resistant to anti-virus MAbs whose neutralizing ability was also abrogated by substitutions at VP2 residues 163 or 164. ND, Not determined. et al., 1979; A1 Moudallal et al., 1982; Cooper et al., 1987; Parry et al., 1990) . None of the mutations, including those within the mapped sequence, completely abolished neutralization. Indeed, with the exception of the reactions with mutant viruses that had changes of VP1 K264E and VP2 N163Y, P033 neutralized mutant viruses considerably more effectively than the HRV2 parent. For example, fourfold greater neutralization was observed with the VP2 P164H mutation. Enhanced neutralization of a mutant virus (VP2 N163Y) was also seen with the anti-viral MAbs 801 and 829. Increased neutralization resulting from a single amino acid substitution has only been reported once previously (Ferguson et al., 1986 ). An anti-peptide M A b was shown to neutralize a mutant of poliovirus with a single substitution in VP1 threefold more efficiently than the parent virus. However, a virus with a different substitution at the same position was neutralized less well than the parent. Recent studies using synthetic peptide libraries have shown that pentapeptide sequences containing one or more amino acid substitutions can have higher affinities for antibody binding than the native sequence (Lam et al., 1991) . This may explain the increased neutralization of mutant P164H by M A b P033, since a peptide representing the mutant sequence was more efficient at inhibiting antibody binding to immobilized peptide with the wild-type sequence than the homologous peptide itself in a competitive ELISA (Fig. 3) . However, other mutant peptides in which neutralization was enhanced or reduced did not demonstrate significantly increased or decreased competition (Fig. 3) . Alternatively, since P164 does not appear to be essential for peptide recognition by MAb P033, it is possible that the P164H substitution causes local structural perturbations that improve the presentation of the 156-163 tract to the antibody. Although reduced neutralization by MAb P033 was seen with two of the mutant viruses tested, repeated attempts to select neutralization-resistant variant viruses with this antibody itself were unsuccessful.
Somewhat surprisingly, these studies have demonstrated that there is no clear correlation between the minimum binding sequence of an antibody and its specificity. Although some MAbs that do not recognize virus have epitopes which include amino acids that are probably inaccessible on the virus surface, other MAbs in groups 1, 2 and 3 can share the same binding footprint and critical residues. We have reported previously that for MAbs in groups 1 and 2 the ability to neutralize virus is not related to functional affinity, but may be due in part to antibody valency (Barnett et al., 1993) ; the neutralizing MAbs are oligomeric, being of either the IgA or IgM class. One group 3 antibody (P019) is also an IgA, however, and has the same minimum footprint as MAbs in groups 1 and 2 (Table 1 ). The reason for the failure of those group 3 MAbs which have the same minimum binding requirements as MAbs in groups 1 and 2 to readily recognize virus particles currently remains undefined; it is likely to be due to differences in epitope conformation of the six amino acids (VP2 160-165) recognized by MAbs in the three reaction groups. These differences will only be clarified by structural studies of antibody-peptide complexes.
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